[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
Search By NCT Number
Search By Keyword
Genetics & Targets
Phases
Primary Purpose
Country
State
Showing 853 trials matching your filters.
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently sta...

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Dexamethasone

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Ph...
To compare an investigational oral form of the drug cladribine to the FDA approved form of the drug when it is given by vein (IV).

DRUG: Cladribine

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell ...
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.

DRUG: Fludarabine phosphate

DRUG: Cyclophosphamide

DRUG: NY-ESO-1 TCR/IL-15 NK

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma
Background: Primary effusion lymphoma (PEL) is an aggressive form of cancer that affects cells in the immune system and lymph nodes. How PEL develops is not well understood, and this disease does not respond well to standard treatments for other typ...

DRUG: Daratumumab SC

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in...

DRUG: IKS03

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.

DRUG: Reduced Toxicity Ablative Regimen

DRUG: Reduced Intensity Preparative Regimen

DRUG: Myeloablative Preparative Regimen

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE ...
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

DRUG: Teclistamab

DRUG: Talquetamab

DRUG: Daratumumab SC

A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with...

DRUG: Cohort A1 & A2

DRUG: Cohort C1 & C2

DRUG: Cohort D

Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory ...
This phase I trial tests the safety, side effects, and best dose of palbociclib or tazemetostat in combination with CPX-351 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or does not respond to treatment (refract...

DRUG: Tazemetostat

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Biospecimen Collection

DRUG: Palbociclib

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior ...
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients...

DRUG: Zanubrutinib

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles...

PROCEDURE: Computed Tomography

PROCEDURE: Endoscopic Procedure

RADIATION: Involved-site Radiation Therapy (3 Fractions)

RADIATION: Involved-site Radiation Therapy (12 Fractions)

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

DRUG: NX-2127

Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute My...
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the gro...

DRUG: Decitabine

DRUG: Quizartinib

DRUG: Venetoclax

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD...
This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not res...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Dexamethasone

PROCEDURE: Echocardiography

BIOLOGICAL: Elotuzumab

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mezigdomide

PROCEDURE: X-Ray Imaging

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.

DRUG: APG2575

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Pa...
This is an open-label Phase Ia/Ib clinical study of tagraxofusp-erzs, a novel cytokine-drug conjugate that links interleukin-3 with a truncated diphtheria toxin, in combination with gemtuzumab ozogamicin for patients with relapsed/refractory AML. Th...

DRUG: Dose Escalation -tagraxofusp-erzs

DRUG: Dose Expansion at RP2D -tagraxofusp-erzs

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF W...
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those w...

DRUG: TL-895

DRUG: Ruxolitinib

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the imm...

DRUG: Isatuximab

OTHER: Standard Procedures

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or Hi...
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibi...

DRUG: Imetelstat

DRUG: Best Available Therapy (BAT)

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell...
Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. Researchers want to see if this treatment ...

BIOLOGICAL: CD22CART cell infusion

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. I...

DRUG: Purified regulatory T-cells (Treg) plus CD34+ HSPC

DRUG: Fludarabine

DRUG: Melphalan

DEVICE: CliniMACS CD34 Reagent System

DRUG: Tacrolimus

DRUG: Cyclophosphamide

DRUG: Plerixafor

DRUG: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent

DRUG: Thiotepa

DRUG: Mycophenolate Mofetil (MMF)

DRUG: Ruxolitinib

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Tr...
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail ...

DRUG: Bortezomib

DRUG: Daratumumab and Hyaluronidase-fihj

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase M...
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemoth...

DRUG: Decitabine

DRUG: Ruxolitinib

DRUG: Fedratinib

OTHER: Questionnaire Administration

DRUG: Pacritinib

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/...
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

DRUG: Cevostamab

DRUG: Tocilizumab

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with t...

DRUG: Mogamulizumab

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating P...
This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab,...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

BIOLOGICAL: Ofatumumab

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most co...

DRUG: ABBV-319

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatm...

DRUG: KRT-232

DRUG: TL-895

Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies Afte...
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adu...

BIOLOGICAL: Allogeneic T cell progenitors, cultured ex-vivo

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory ...
This phase I/II trial studies the safety of the combination of bortezomib, dexamethasone, and pembrolizumab with or without pelareorep in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refract...

DRUG: Bortezomib

DRUG: Dexamethasone

BIOLOGICAL: Pelareorep

BIOLOGICAL: Pembrolizumab

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity imp...

BEHAVIORAL: CHAMPS-II adapted to adults 60+ years in HCT setting

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

PROCEDURE: Laparoscopically harvested omental tissue autograft

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic...
This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their can...

DRUG: Choline Salicylate

DRUG: Selinexor

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple My...
This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells ...

DRUG: Dexamethasone

DRUG: Leflunomide

DRUG: Pomalidomide

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Par...
This study is a rolling arm study of pembrolizumab in combination with investigational agents in pediatric participants with relapsed or refractory classical Hodgkin lymphoma (cHL) solid tumors with microsatellite instability-high (MSI-H)/mismatch re...

BIOLOGICAL: Pembrolizumab

BIOLOGICAL: Favezelimab

BIOLOGICAL: Favezelimab/Pembrolizumab

BIOLOGICAL: Vibostolimab

BIOLOGICAL: Pembrolizumab/Vibostolimab

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (...

DRUG: KITE-197

DRUG: Cyclophosphamide

DRUG: Fludarabine

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed o...
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or that ...

DRUG: Dasatinib

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Venetoclax

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic...
This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking so...

DRUG: Azacitidine

DRUG: Seclidemstat

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizuma...
This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the following hematological malignancies: * classical Hodgkin lymphoma (cH...

BIOLOGICAL: pembrolizumab

BIOLOGICAL: Favezelimab

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient...
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

DRUG: Cyclophosphamide

DRUG: Cyclosporine

PROCEDURE: Diagnostic Imaging

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

OTHER: Survey Administration

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-...
Bruton's tyrosine kinase inhibitors (BTKi), anti-CD20 antibodies, and the B cell lymphoma 2 inhibitor (BCL-2i) venetoclax are drug classes used to treat patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Anti-CD20 therap...

DRUG: Zanubrutinib Pill

DRUG: Venetoclax Pill

DRUG: Obinutuzumab Injection

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignan...
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant pe...

PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT

DRUG: Zoledronate

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow ...
Background: * Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia. Allogenic stem cell transplants encourage the g...

DEVICE: Miltenyi CD34 Reagent System

OTHER: Donor derived G-CSF mobilized PBC

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted stand...

DRUG: NMS-03597812

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
This is a gene transfer study for patients with a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) that has come back or has not gone away after treatment. The body has different ways of fighting infection and disease. No single way se...

GENETIC: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased...

DRUG: 5-azacytidine

DRUG: Decitabine

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML...

DRUG: Bleximenib

DRUG: Venetoclax (VEN)

DRUG: Azacitidine (AZA)

DRUG: Cytarabine

DRUG: Daunorubicin or Idarubicin

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.

DRUG: DaraVRD

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: KITE-363

BIOLOGICAL: KITE-753

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refract...
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas...

DRUG: LP-284

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).

DRUG: AK117

DRUG: Placebo

DRUG: Azacitidine

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syn...
The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid l...

DRUG: CTX-712

KRT-232 and TKI Study in Chronic Myeloid Leukemia
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is ...

DRUG: KRT-232

DRUG: Dasatinib

DRUG: Nilotinib

Gene Therapy for B-Cell Acute Lymphoblastic Leukemia
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL).

GENETIC: Dose Level 1, VNX-101

GENETIC: Dose Level 2, VNX-101

GENETIC: Dose Level 3, VNX-101

GENETIC: Dose Level 4, VNX-101

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodie...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Decitabine and Cedazuridine

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

BIOLOGICAL: P-BCMA-ALLO1 CAR-T cells

DRUG: Rimiducid

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML. IV NEROFE will be administered three times per week on alte...

DRUG: Nerofe

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Re...
This phase II trial tests how well decitabine and cedazuridine (DEC-C) works in combination with venetoclax in treating acute myeloid leukemia (AML) in patients whose AML has come back after a period of improvement (relapse) after a donor stem cell t...

DRUG: Venetoclax

DRUG: Decitabine

DRUG: Cedazuridine

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Biospecimen Collection

Elimination of Minimal Residual Disease After Transplant
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Worki...

DRUG: Dexamethasone

DRUG: Isatuximab

DRUG: Lenalidomide

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Natural killer cells are a type of i...

DRUG: Cytarabine Hydrochloride

DRUG: Fludarabine

BIOLOGICAL: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants W...
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The p...

DRUG: Bomedemstat

DRUG: Anagrelide

DRUG: Busulfan

DRUG: Interferon alfa/pegylated interferon alfa

DRUG: Ruxolitinib

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase...

DRUG: CYC140

Blinatumomab Bridging Therapy
The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.

DRUG: Blinatumomab

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study...

DEVICE: CliniMACS

Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic sy...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Leucovorin

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Dexrazoxane

DRUG: Calaspargase Pegol

DRUG: Erwinia asparaginase

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelody...
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).

BIOLOGICAL: Luspatercept

BIOLOGICAL: Epoetin Alfa

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adul...
The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combinati...

DRUG: gilteritinib

DRUG: fludarabine

DRUG: cytarabine

DRUG: granulocyte colony-stimulating factor (G-CSF)

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone ...
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycl...

DRUG: Mosunetuzumab

DRUG: Lenalidomide

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
This is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety an...

DRUG: Venetoclax Oral Tablet

DRUG: Daunorubicin

DRUG: Cytarabine

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants Wi...
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

DRUG: Loncastuximab Tesirine

DRUG: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleu...
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (...

DRUG: Fecal Microbiota Transplantation

PROCEDURE: Chemotherapy

PROCEDURE: CAR-T Therapy

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Particip...
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

DRUG: Golcadomide

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related distorted taste (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characteriz...

DRUG: Talquetamab

DRUG: Prophylaxis A

DRUG: Prophylaxis B

DRUG: Prophylaxis C

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positi...
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (...

PROCEDURE: CS1-CAR T Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the ...
This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasi...

DRUG: Acalabrutinib

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Lenalidomide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Relapsed/Ref...
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

DRUG: ATA3219

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloprolif...

DRUG: INCA033989

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutan...
This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that ha...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Mogamulizumab

BIOLOGICAL: Natural Killer Cell Therapy

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only...

DRUG: Chemotherapy

BIOLOGICAL: Cell infusion

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well ...
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participa...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prenisolone

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that ha...

DRUG: Isatuximab

DRUG: Pomalidomide

DRUG: Dexamethasone

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are control...

DRUG: Isatuximab

DRUG: Dexamethasone

DRUG: Pomalidomide

DRUG: Belantamab mafodotin

DRUG: Pegenzileukin

DRUG: SAR439459

DRUG: Belumosudil

DRUG: Evorpacept

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in ...

DRUG: Mosunetuzumab

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Seco...
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities ...

DRUG: Pegylated interferon alpha2a

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelody...
This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a t...

DRUG: Ivosidenib

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1b Study of R289 in Participants with Lower-risk Myelodysplastic Syndromes (LR MDS)

DRUG: R906289 Monosodium (R289 Na)

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuz...
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

DRUG: Sonrotoclax

DRUG: Zanubrutinib

DRUG: Venetoclax

DRUG: Obinutuzumab

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukem...
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).

DRUG: Ruxolitinib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Vincristine

DRUG: Pegaspargase

DRUG: Rituximab

DRUG: Methotrexate (Intrathecal Administration)

DRUG: Methotrexate (Intravenous Administration)

DRUG: Dexamethasone

DRUG: Doxorubicin

DRUG: Thioguanine

DRUG: Methotrexate Oral Product

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple M...
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

DRUG: Selinexor

DRUG: Venetoclax

DRUG: Dexamethasone

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Ris...
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction...

DRUG: Thiotepa

DRUG: Cyclophosphamide

DRUG: Melphalan

DRUG: Etoposide

DRUG: Carboplatin

BIOLOGICAL: Autologous Stem Cell Infusion

BIOLOGICAL: Granulocyte colony stimulating factor

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MD...
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.

DRUG: Luspatercept

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymp...
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Venetoclax

Phase IB/II of CPX-351 for Relapse Prevention in AML
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, e...

DRUG: CPX-351

Acalabrutinib in CNSL
This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).

DRUG: Acalabrutinib

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelst...
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat in ...

DRUG: Imetelstat

DRUG: Ruxolitinib

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood St...
The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, redu...

DRUG: Hyperbaric oxygen

CONFIRM: Magnetic Resonance Guided Radiation Therapy
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved ...

RADIATION: Viewray MRIdian® Linac

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory...
This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed ...

GENETIC: ALLO-501A

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

First in Human, Dose Escalation Study of AN4005
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. E...

DRUG: AN4005-dose level 0

DRUG: AN4005-dose level 1

DRUG: AN4005-dose level 2

DRUG: AN4005-dose level 3

DRUG: AN4005-dose level 4

DRUG: AN4005-food effect

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most pati...

BIOLOGICAL: iC9-CAR19 T cells

DRUG: Bendamustine

DRUG: Fludarabine

DRUG: AP1903

DRUG: Cyclophosphamide

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azac...
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

DRUG: Ziftomenib

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Daunorubicin

DRUG: Cytarabine

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment the investigators kno...

BIOLOGICAL: Dose Level 1A: 2 x 10^7 cells/m2

BIOLOGICAL: Dose Level 2A: 6 x 10^7 cells/m2

BIOLOGICAL: Dose Level 2B: 6 x 10^7 cells/m2

BIOLOGICAL: Dose Level 3B: 2 x 10^8 cells/m2

BIOLOGICAL: Dose Level 3A: 2 x 10^8 cells/m2

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy. The study will estimate th...

DRUG: Ibrutinib

DRUG: Venetoclax

DRUG: Acalabrutinib

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemoth...
The primary purpose of this study is to determine complete remission rate of a novel combination induction chemotherapy treatment based upon 20 patients with newly diagnosed secondary AML.

DRUG: Venetoclax

DRUG: FLAG or CLAG Protocol

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradi...
This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplant...

DRUG: Evomela

DRUG: Fludarabine

RADIATION: Total Body Irradiation

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib...
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of c...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Ibrutinib

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

DRUG: Venetoclax

Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma...
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

DRUG: Isatuximab

DRUG: lenalidomide

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patient...
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBC...

DRUG: Glofitamab

DRUG: Tocilizumab

DRUG: Obinutuzumab

DRUG: Gemcitabine

DRUG: Oxaliplatin

An Extension Study for Patients Previously Enrolled in Studies with Pelabresib
The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and leukemia...

DRUG: Pelabresib

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

BIOLOGICAL: CNTY-101

BIOLOGICAL: IL-2

DRUG: Lymphodepleting Chemotherapy

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the stud...

DRUG: Zanubrutinib

DRUG: Tafasitamab

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloprolif...
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syn...

BIOLOGICAL: Axatilimab

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

OTHER: Survey Administration

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hemat...
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to eva...

DRUG: IDP-023

DRUG: Rituximab

DRUG: Daratumumab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

BIOLOGICAL: anitocabtagene-autoleucel

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.

DRUG: Mogamulizumab-Kpkc

DEVICE: Phototherapy

Olutasidenib for the Treatment of Patients with IDH1 Mutated AML, MDS or CMML After Donor Hematopoie...
This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelo...

PROCEDURE: Biospecimen Collection

DRUG: Olutasidenib

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Spleno...
To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

DRUG: Ruxolitinib

PROCEDURE: Allogeneic Stem Cell Transplantation

DRUG: Levetiracetam

DRUG: Eltrombopag

DRUG: Busulfan

DRUG: Romiplostim

DRUG: Fludarabine phosphate

DRUG: Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malign...
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

BIOLOGICAL: OrcaGraft (Orca-Q)

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

DRUG: HDP-101

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (M...

DRUG: Tazemetostat Pill

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myelopr...
This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL m...

DRUG: Azacitidine

DRUG: Quizartinib

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment ...

DRUG: ARV-393

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multi...
The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with I...

DRUG: Iberdomide

DRUG: Daratumumab/rHuPH20 Co-formulation

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune ...
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy f...

DRUG: Siltuximab

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomal...
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone ...

DRUG: Talquetamab

DRUG: Pomalidomide

DRUG: Teclistamab

DRUG: Elotuzumab

DRUG: Dexamethasone

DRUG: Bortezomib

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: * Dendritic Cell/AML Fusion vacci...

DRUG: decitabine

BIOLOGICAL: DC/AML fusion cells

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Pat...
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have ...

BEHAVIORAL: Behavioral Intervention

DRUG: Beta-Adrenergic Antagonist

DRUG: Propranolol

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

OTHER: Resistance Training

OTHER: Short-Term Fasting

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute My...
This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemothe...

DRUG: Gemtuzumab Ozogamicin

OTHER: Quality-of-Life Assessment

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multip...
This phase I trial finds out the best dose and side effects of venetoclax and tocilizumab in treating patients with t(11;14) multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Venetoclax may stop the growth ...

BIOLOGICAL: Tocilizumab

DRUG: Venetoclax

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lym...
The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the c...

DRUG: Venetoclax Oral Tablet [Venclexta]

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have receiv...

DRUG: Brentuximab vedotin

DRUG: Pembrolizumab

Cladribine Venetoclax in Monocytic AML
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax

DRUG: Cladribine

DRUG: Venetoclax

DRUG: Azacitidine

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malig...

BIOLOGICAL: Orca-Q

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplasti...
This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received...

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to ...
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

DRUG: Tazemetostat

DRUG: Zanubrutinib

PLAT-08: a Study of SC-DARIC33 CAR T Cells in Pediatric and Young Adults with Relapsed or Refractory...
A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility...

BIOLOGICAL: SC-DARIC33

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte At...
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The ...

DRUG: TAB004

DRUG: Toripalimab

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in...
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will...

DRUG: Elranatamab

DRUG: Iberdomide

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 pri...

DRUG: AZD0486

ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the abil...

BIOLOGICAL: ADCT-602

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing...
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that ma...

DRUG: Loratadine

OTHER: Placebo

OTHER: Questionnaire Administration

A Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer
This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid ...

DRUG: REC-1245

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion c...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Mitoxantrone

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-...
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.

DRUG: APG-115

DRUG: APG-2575

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 M...
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to det...

DRUG: revumenib

DRUG: cobicistat

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T...
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and yo...

DRUG: Daratumumab

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction Wi...
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identi...

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: CAR.5/IL15-transduced CB-NK cells

Studying TAK-243 in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or dist...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

PROCEDURE: Magnetic Resonance Imaging

DRUG: UAE Inhibitor TAK-243

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is...

DRUG: BXCL701

Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell ...
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venet...

DRUG: Venetoclax

DRUG: Ibrutinib

DRUG: Prednisone

BIOLOGICAL: Obinutuzumab

DRUG: Revlimid (lenalidomide)

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient S...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess th...

DRUG: Epcoritamab

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or Hig...
The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

BIOLOGICAL: SPRX002

BIOLOGICAL: ARC-T Cells

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myelo...
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product ca...

DRUG: Dasatinib

DRUG: Imatinib Mesylate

OTHER: Laboratory Biomarker Analysis

DRUG: Nilotinib

BIOLOGICAL: Pembrolizumab

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leuke...
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. F...

DRUG: Asciminib Pediatric formulation group

DRUG: Asciminib Adult formulation group

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma
The purpose of this study is to test the safety of N-AC when given in combination with Yescarta to people with lymphoma. This study will test different doses of N-AC to find the highest dose that causes few or mild side effects in participants.

DRUG: N-Acetylcysteine

A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutati...
A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.

DRUG: DSP-5336

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Background: Myelodysplastic syndromes (MDS) are diseases that affect the bone marrow. They can inhibit the blood formation process and reduce blood cell counts. High-risk MDS can lead to leukemia. People with high-risk MDS have a low survival rate. ...

DRUG: KPT-8602

DRUG: Inqovi

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalat...

DRUG: CC-96191

CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult...

BIOLOGICAL: Cohort 1

BIOLOGICAL: Cohorts 2

BIOLOGICAL: Cohort 3

UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1
This open-label, single arm Phase I trial aims to determine the safety and tolerability of anti-CD19 chimeric antigen receptor-expressing (CAR) T cells (UCD19 CAR T) in adults B-ALL that are in first complete remission with minimal residual disease (...

DRUG: CD19 Directed CAR T Cell

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-ch...

DRUG: CAP-100

LMY-920 for Treatment of Relapsed or Refractory Myeloma
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following ...

BIOLOGICAL: Autologous CAR-T cell therapy expressing the BAFF-ligand.

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With ...
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

DRUG: Eflapegrastim

DRUG: Chemotherapy

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Ther...
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

DRUG: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine phosphate

DRUG: Prednisone

DRUG: Diphenhydramine

DRUG: Acetaminophen

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
The current standard-of-care for Hairy Cell Leukemia involves chemotherapy, with agents such as cladribine or pentostatin. Chemotherapy is associated with infection, low blood counts and predisposition to future cancers. This study tests a new yet pr...

DRUG: Low dose vemurafenib plus rituximab

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute...
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that i...

DRUG: LP-118

DRUG: Ponatinib

DRUG: Vincristine

DRUG: Dexamethasone

DRUG: Methotrexate

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transpla...
This phase II trials studies the effect of treosulfan-based versus clofarabine-based conditioning regimens before donor hematopoietic stem cell transplant in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Chemotherapy dru...

DRUG: Clofarabine

DRUG: Fludarabine

PROCEDURE: Hematopoietic Cell Transplantation

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Lumbar Puncture

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Biospecimen Collection

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp ...
This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be ad...

DRUG: Englumafusp alfa

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Tocilizumab

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematolo...
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high. Researchers want to see if giving the transplant recipient an infusion of lymphocytes (a type of white...

PROCEDURE: donor lymphocyte infusion

DRUG: Cyclophosphamide

DRUG: Busulfan

DRUG: Mycophenolate mofetil

DRUG: Fludarabine

DRUG: Sirolimus

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myelo...
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has co...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Computed Tomography

BIOLOGICAL: Mezigdomide

PROCEDURE: Positron Emission Tomography

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of th...

BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Rituximab

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

BIOLOGICAL: MCARH125

BIOLOGICAL: MCARH109

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly ...
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclona...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Glofitamab

DRUG: Lenalidomide

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these ri...

DRUG: Busulfan

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Mycophenolate Mofetil

DRUG: Sirolimus

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, S...
This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatm...

DRUG: Atezolizumab

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD2...
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

DRUG: AZD5492

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewa...

BIOLOGICAL: ECT-001-CB (UM171-Expanded Cord Blood Transplant)

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutat...
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophospha...

DRUG: NeoVax

DRUG: Cyclophosphamide

DRUG: Pembrolizumab

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Background: - Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: - To test the safety and effic...

DRUG: Bortezomib plus Clofarabine

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid...
This phase Ib trial tests the safety, side effects, and best dose of a enasidenib in combination with cobimetinib in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Enasidenib...

DRUG: Cobimetinib

DRUG: Enasidenib Mesylate

A Safety Study of SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lympho...

DRUG: SGN-35C

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit N...
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal to...

DRUG: BST-236

DRUG: venetoclax

Avo in R/R and Previously Untreated MCL
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in th...

DRUG: Acalabrutinib

DRUG: Venetoclax

DRUG: Obinutuzumab

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia,...
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as c...

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Gilteritinib

DRUG: Idarubicin

OTHER: Laboratory Biomarker Analysis

DRUG: Midostaurin

DRUG: Venetoclax

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * ...

DRUG: Pirtobrutinib

DRUG: Venetoclax

A Study of Radiation Therapy Before CAR T Cell Therapy for People with B Cell Lymphoma
The purpose of this study is to test whether radiation therapy given before standard CAR T cell therapy is a safe and effective treatment for people with relapsed and refractory B cell lymphoma. The researchers will also study whether radiation thera...

RADIATION: Bridging radiotherapy (BRT)

DRUG: Conditioning chemotherapy

BIOLOGICAL: CAR T-cell product

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Ris...
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).

DRUG: Cilta-cel

DRUG: Talquetamab

DRUG: Daratumumab

DRUG: Lenalidomide

DRUG: Dexamethasone

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells wi...

BIOLOGICAL: ATLCAR.CD30 T cells

DRUG: Bendamustine

DRUG: Fludarabine

DRUG: Cyclophosphamide

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed...
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a ...

BIOLOGICAL: SCRI-CAR22v2

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations...
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

DRUG: BMS-986393

DRUG: Alnuctamab

DRUG: Mezigdomide

DRUG: Iberdomide

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes...
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment...

BIOLOGICAL: Tumor associated antigen lymphocytes (TAA-T)

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malign...
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell l...

BIOLOGICAL: Zilovertamab vedotin

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantat...
This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the rel...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Fludarabine Phosphate

BIOLOGICAL: Granulocyte Colony-Stimulating Factor

PROCEDURE: Hematopoietic Cell Transplantation

PROCEDURE: Intensity-Modulated Radiation Therapy

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

Venetoclax to Augment Epigenetic Modification and Chemotherapy
The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.

DRUG: Venetoclax

DRUG: Azacitadine

DRUG: Vorinostat

DRUG: Cytarabine

DRUG: Fludarabine

DRUG: Filgrastim

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple...
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to stan...

DRUG: Belantamab mafodotin

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Dexamethasone

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Mye...
To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.

DRUG: Decitabine

DRUG: Listaftoclax

DRUG: Olverembatinib

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal can...

DRUG: Pomalidomide

DRUG: Nivolumab

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

DRUG: CTX-8371

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), Hi...
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax

DRUG: Azacitidine

DRUG: SL-401

DRUG: Venetoclax

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

DRUG: Efineptakin alfa

DRUG: Tisagenlecleucel

DRUG: Axicabtagene ciloleucel

DRUG: Lisocabtagene Maraleucel

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia
To find a recommended dose of HC-7366 that can be given in combination with azacitidine and venetoclax to patients with AML. The safety and effects of this drug combination will also be studied.

DRUG: HC-7366

DRUG: Azacitidine

DRUG: Venetoclax

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphobla...
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase ...

BIOLOGICAL: BEAM-201

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Thera...
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.

DRUG: Acalabrutinib

DRUG: Rituximab

OTHER: Brexucabtagene Autoleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine ...
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of ...

DRUG: Venetoclax

DRUG: cBTKi Monotherapy

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With ...
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alon...

PROCEDURE: Biospecimen Collection

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Oral Azacitidine

DRUG: Prednisone

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

Elranatamab in R/R Multiple Myeloma
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

DRUG: Elranatamab

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (G...

DRUG: Total Body Irradiation (TBI) (Plan 1)

DRUG: Cyclophosphamide (CY) (Plan 1)

DRUG: Fludarabine (FLU)

DRUG: Methylprednisolone (MP)

DEVICE: Donor mobilized PBSC infusion

DRUG: G-CSF

DRUG: Cyclophosphamide (CY) (Plan 2)

DRUG: Rituximab

DRUG: Busulfan

DRUG: Alemtuzumab

DRUG: Melphalan

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML...
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mut...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Gilteritinib

DRUG: Venetoclax

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostauri...
This phase I study hopes to explore how safe and tolerable is the combination of gemtuzumab ozogamicin (GO) and midostaurin, with the standard induction therapy (cytarabine and daunorubicin) in patients with newly diagnosed FLT-3 mutated Acute Myeloi...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Gemtuzumab Ozogamicin

DRUG: Midostaurin

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack y...

BIOLOGICAL: CD33KO-HSPC; CART33

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) ...
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolera...

DRUG: Elranatamab

DRUG: Carfilzomib

DRUG: Maplirpacept

Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

DRUG: Niclosamide

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Ne...
This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination therapy in treating p...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Idarubicin

PROCEDURE: Multigated Acquisition Scan

DRUG: Pivekimab Sunirine

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Personalized Autologous Transplant for Multiple Myeloma
This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells,...

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

DRUG: Melphalan

OTHER: Questionnaire Administration

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently pursued management option for CTCL, especially in patients with more ad...

DRUG: Imiquimod

RADIATION: Radiation Therapy

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Background: - GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transp...

PROCEDURE: Allogeneic HSCT

DRUG: Busulfan Test dose

DRUG: Fludarabine (Fludara, Berlex Laboratories)

DRUG: Busulfan (Busulfex)

DRUG: Cyclophosphamide (CTX, Cytoxan)

PROCEDURE: Total Body Irradiation (TBI)

DRUG: Mycophenolate mofetil (MMF)

DRUG: Tacrolimus

BIOLOGICAL: Equine Anti-Thymocyte Globulin

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adu...
This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The tri...

BIOLOGICAL: CD33CART autologous

BIOLOGICAL: CD33CART allogeneic

Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnos...

DRUG: Selinexor

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

DRUG: Bortezomib

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Ixazomib

DRUG: Elotuzumab

DRUG: Clarithromycin

DRUG: Belantamab Mafodotin

DRUG: Mezigdomide

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients...
This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple myeloma that has come bac...

DRUG: Carfilzomib

DRUG: Dexamethasone

DRUG: Pomalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Selinexor

PROCEDURE: X-Ray Imaging

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safet...

DRUG: Talquetamab

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acu...
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunor...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

PROCEDURE: Echocardiography

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

PROCEDURE: Multigated Acquisition Scan

DRUG: Venetoclax

(Apex) Bezuclastinib in Patients with Advanced Systemic Mastocytosis
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cel...

DRUG: bezuclastinib

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

DRUG: VIP943 (QW)

DRUG: VIP943 (BIW)

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B...

DRUG: AZD0486 IV

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple ...
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or...

DRUG: Elranatamab

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone

DRUG: Bortezomib

DRUG: Carfilzomib

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects...

DRUG: Loncastuximab tesirine 150 µg/Kg

DRUG: Loncastuximab tesirine 75µg/Kg

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignanc...
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine ...

DRUG: Tagraxofusp

DRUG: Fludarabine

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Azacitidine

DRUG: Methotrexate

DRUG: Cytarabine IT

DRUG: Hydrocortisone

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Maligna...
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

BIOLOGICAL: CTX112

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes n...

DRUG: Azacitidine

DRUG: Enasidenib

OTHER: Quality-of-Life Assessment

Orphan Indications for CD19 Redirected Autologous T Cells
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients w...

BIOLOGICAL: Murine CART19

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients ...
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherapy drug cyclophosphamide helps reduce the risk and ...

DRUG: Mycophenolate Mofetil

PROCEDURE: Allogeneic HSCT

DRUG: Fludarabine

DRUG: Sirolimus

DRUG: Filgrastim

DRUG: Cyclophosphamide

DRUG: Mesna

PROCEDURE: Total Body Irradiation (TBI)

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis wit...
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related ...

DRUG: Decitabine

DRUG: Filgrastim

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered H...
The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to a...

DRUG: BLU-263

DRUG: Azacitidine

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Ph...
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cance...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Ruxolitinib

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory...
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal anti...

DRUG: Carfilzomib

DRUG: Dexamethasone

BIOLOGICAL: Isatuximab

DRUG: Pomalidomide

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Skeletal Survey X-Ray

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Youn...
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult parti...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

DRUG: Tocilizumab

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in ...
This is an open-label study, where participants will be given ceftolozane-tazobactam as the primary treatment for Pseudomonas aeruginosa infections. Open-label means both the investigator and the participant will known what drug will be given. Partic...

DRUG: Ceftolozane / Tazobactam Injection

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Dacarbazine

DRUG: Doxorubicin

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Vinblastine

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumo...

DRUG: RNK05047

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin ...
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzu...

DRUG: Polatuzumab vedotin

Co-administration of CART22-65s and huCART19 for B-ALL
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)

BIOLOGICAL: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

DRUG: Venetoclax

DRUG: Lenalidomide

DRUG: Rituximab

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referre...

DRUG: Descartes-15

Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmac...

DRUG: SLN124

DRUG: Placebo

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daun...
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

DRUG: Daunorubicin

PROCEDURE: Multigated Acquisition Scan

DRUG: Revumenib

PROCEDURE: Transthoracic Echocardiography

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relap...
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

DRUG: Tafasitamab

DRUG: Lenalidomide

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the f...

DRUG: Iberdomide

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Di...
This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatme...

DRUG: Duvelisib

BIOLOGICAL: Tisagenlecleucel

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of zif...

DRUG: Ziftomenib

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

DRUG: Dasatinib

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Rela...
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) ma...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Bendamustine

DRUG: Lenalidomide

DRUG: Tocilizumab

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated with Antibody Therapy, Checkpoint Inhibit...
This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary mediastinal large B-cell lympho...

DRUG: Brentuximab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin

BIOLOGICAL: Nivolumab

DRUG: Prednisone

OTHER: Quality-of-Life Assessment

BIOLOGICAL: Rituximab

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+...
This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as b...

DRUG: Brentuximab Vedotin

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Nivolumab

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (h...
This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor. If MTX proves to be safe and tolerable with a signal o...

DRUG: Methotrexate (MTX)

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell ...
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

DRUG: JNJ-68284528

DRUG: Lenalidomide

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Dexamethasone

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With ...
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a prote...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

OTHER: Fludeoxyglucose F-18

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

ATRA and Carfilzomib in Plasma Cell Myeloma Patients
This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM...

DRUG: All-Trans Retinoic Acid (ATRA) Dose 0

DRUG: All-Trans Retinoic Acid (ATRA) Dose -1

DRUG: All-Trans Retinoic Acid (ATRA) Dose 1

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomid...
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to...

DRUG: Linvoseltamab

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone

Ponatinib Hydrochloride As Second Line Therapy in Treating Patients with Chronic Myeloid Leukemia in...
This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, ...

OTHER: Laboratory Biomarker Analysis

DRUG: Ponatinib Hydrochloride

OTHER: Quality-of-Life Assessment

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Tr...
To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received tre...

DRUG: Pirtobrutinib

DRUG: Obinutuzumab

DRUG: Venetoclax

DRUG: Valacyclovir

DRUG: Allopurinol

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (I...
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) ther...

DRUG: Venetoclax

DRUG: Obinutuzumab

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of ...

DRUG: Azacytidine

DRUG: Romidepsin

DRUG: Belinostat

DRUG: Pralatrexate

DRUG: Gemcitabine

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndrome...
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.

DRUG: Tebapivat

Avatrombopag Vs. Placebo for CIT in GI Malignancies
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy....

DRUG: Avatrombopag

DRUG: Matching Placebo

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Bortezomib Injection

DRUG: Dexamethasone

A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherap...
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a pr...

DRUG: Alintegimod

DRUG: Ipilimumab

DRUG: Nivolumab

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CA...

DRUG: Talquetamab

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Background: Runt-related transcription factor 1 (RUNX1) gene regulates the formation of blood cells. People with mutations of this gene may bleed or bruise easily; they are also at higher risk of getting cancers of the blood, bone marrow, and lymph ...

DRUG: imatinib

DEVICE: TruSight Oncology

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in ...
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to t...

DEVICE: SonoCloud-9 (SC9)

DRUG: Carboplatin

DRUG: Lomustine

DRUG: Temozolomide

Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patient...
This is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in patien...

DEVICE: CliniMACs

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in...
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not receive...

DRUG: Brentuximab vedotin

DRUG: Doxorubicin Hydrochloride

DRUG: Pembrolizumab

DRUG: Dacarbazine

IS-free Treg HaploHCT
This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) rec...

RADIATION: Radiation

DRUG: Fludarabine

DRUG: Thiotepa

DRUG: Cyclophosphamide

DRUG: Mesna

BIOLOGICAL: Treg-enriched donor cell

BIOLOGICAL: Unmodified donor T Cell

PROCEDURE: CD34+ Haplo Peripheral Blood Stem Cell

TmCD19-IL18 in CD19+ Cancers
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers. This study will take place in two pa...

BIOLOGICAL: TmCD19-IL18

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated wi...

DRUG: bendamustine

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Bleomycin

DRUG: Vincristine

DRUG: Vinblastine

DRUG: Prednisone

DRUG: Filgrastim

DRUG: Brentuximab Vedotin

DRUG: Cyclophosphamide

DRUG: DTIC

OTHER: Quality of Life Measurements

RADIATION: Radiotherapy

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Tria...
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways t...

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Carfilzomib

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

PROCEDURE: Multigated Acquisition Scan

Safe Accelerated Venetoclax Escalation in CLL
This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome (TLS), are able to safely ...

DRUG: Venetoclax

DRUG: Obinutuzumab

DRUG: Rituximab

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refr...
This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodi...

DRUG: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen

DRUG: Cladribine and Cytarabine (CLLDAC) Regimen

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination Wit...
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended do...

DRUG: Loncastuximab Tesirine

DRUG: Polatuzumab Vedotin

DRUG: Glofitamab

DRUG: Mosunetuzumab

DRUG: Obinutuzumab

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will rece...

DRUG: Polatuzumab Vedotin

DRUG: Rituximab

DRUG: Etoposide

DRUG: Prednisone

DRUG: Cyclophosphamide

DRUG: Hydroxydaunomycin

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided ...

DRUG: Azacitidine

DRUG: Selumetinib

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

DRUG: ISB 2001

DRUG: ISB 2001

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.

DRUG: Glipizide

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induct...
This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide + G-CSF mobilization, and in addition, assesses the pharmacodynamics (PD) of motix...

DRUG: Motixafortide

DRUG: G-CSF

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Oz...
This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this stu...

DRUG: Inotuzumab ozogamicin

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Methotrexate

DRUG: Vincristine

DRUG: Ponatinib

DRUG: Methotrexate for Injection

PROCEDURE: Allogenic Stem Cell Transplantation

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refracto...
This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to tre...

DRUG: Acalabrutinib

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transfor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

BIOLOGICAL: Lisocabtagene Maraleucel

PROCEDURE: Lymph Node Biopsy

PROCEDURE: Positron Emission Tomography

DRUG: Zanubrutinib

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel ...

DRUG: Pirtobrutinib

DRUG: Brexucabtagene Autoleucel

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell ...
This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional ex...

PROCEDURE: Graft cell infusion

DRUG: Tacrolimus

DRUG: Mycophenolate mofetil

DRUG: G-CSF

PROCEDURE: CIML NK cell infusion

DRUG: ALT-803

PROCEDURE: Leukapheresis

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to as...

DRUG: DFV890

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maint...
This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission...

DRUG: Decitabine and Cedazuridine

DRUG: Enasidenib

DRUG: Gilteritinib

DRUG: Ivosidenib

DRUG: Venetoclax

Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, d...

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

DRUG: Oral MRT-2359

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leuk...
This phase Ib trial studies the side effects and best dose of pembrolizumab and how well it works in combination with decitabine with or without venetoclax in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is newly-dia...

DRUG: Decitabine

BIOLOGICAL: Pembrolizumab

DRUG: Venetoclax

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

DRUG: Dose escalation: COM902 monotherapy.

COMBINATION_PRODUCT: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

DRUG: Cohort expansion: COM902 (RDFE) monotherapy.

DRUG: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

COMBINATION_PRODUCT: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID. This study consists of Phase 1 and Phase 2 components in subject...

DRUG: Fadraciclib

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or...
This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutini...

BIOLOGICAL: Rituximab

DRUG: Zanubrutinib

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HC...
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).

BIOLOGICAL: VOR33

DRUG: Mylotarg

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Ge...
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

DRUG: Revumenib

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressin...
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research combine...

GENETIC: Autologous CD5.CAR/28zeta CAR T cells

GENETIC: Allogeneic CD5.CAR/28zeta CAR T cells

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alter...
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by...

DRUG: Oral repotrectinib (TPX-0005)

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agen...
This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitid...

DRUG: Azacitidine

DRUG: Decitabine

DRUG: Venetoclax

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transpla...
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to ...

DRUG: SOC + TSC-100

DRUG: SOC + TSC-101

OTHER: Control

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participa...
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the co...

DRUG: Sonrotoclax

DRUG: Zanubrutinib

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid ...
The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is...

DRUG: CIML-NK Cells

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hem...
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell tran...

BIOLOGICAL: Ide-cel (bb2121)

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Mye...
This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide,...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Iberdomide

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With ...
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase ...

DRUG: Bexmarilimab

DRUG: Azacitidine

DRUG: Venetoclax

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Partic...
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relap...

DRUG: ABBV-787

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After...
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.

DRUG: Belantamab mafodotin

DRUG: Lenalidomide

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukem...
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1...

DRUG: Emavusertib

DRUG: Venetoclax

DRUG: Emavusertib

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicu...
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

DRUG: Loncastuximab tesirine

DRUG: Rituximab

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for M...
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following h...

DRUG: Belantamab mafodotin

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Pa...
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

DRUG: Pirtobrutinib

DRUG: Venetoclax

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant ...
This phase I studies the side effects and best dose of total marrow and lymphoid irradiation when given together with fludarabine and melphalan before donor stem cell transplant in treating participants with high-risk acute leukemia or myelodysplasti...

DRUG: Fludarabine

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

RADIATION: Total Marrow Irradiation

CC-486 and Venetoclax for Acute Myeloid Leukemia
This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recomme...

DRUG: Venetoclax

DRUG: CC-486

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractor...
This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or tha...

BIOLOGICAL: Belantamab Mafodotin

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphom...
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with sur...

BIOLOGICAL: Pembrolizumab

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral c...

DRUG: DFP-10917

DRUG: Venetoclax

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic ...
This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the abil...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Tafasitamab

DRUG: Zanubrutinib

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lympho...
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

BIOLOGICAL: BI-1206

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chron...
This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back ...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...
This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Sy...
Patients with clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndromes (MDS) have a life expectancy of 5 to 10 years. Mortality in these patients results from progression of disease to higher-risk MDS or acute mye...

DRUG: Atorvastatin

DRUG: Rosuvastatin

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multi...
This phase I trial tests the side effects and best dose of TGFbi natural killer (NK) cells (TiNK) when given together with isatuximab for the treatment of patients with multiple myeloma that has come back after a period of improvement (relapsed) or t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Dexamethasone

PROCEDURE: Echocardiography

BIOLOGICAL: Isatuximab

OTHER: Questionnaire Administration

BIOLOGICAL: Universal Donor Expanded TGF-beta-imprinted NK Cells

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab V...
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II ...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Bleomycin Sulfate

DRUG: Brentuximab Vedotin

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Dacarbazine

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

DRUG: Etoposide Phosphate

OTHER: Fludeoxyglucose F-18

RADIATION: Involved-site Radiation Therapy

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

DRUG: Prednisone

DRUG: Procarbazine Hydrochloride

OTHER: Questionnaire Administration

DRUG: Vinblastine Sulfate

DRUG: Vincristine Sulfate

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabr...

DRUG: ACALABRUTINIB

DRUG: LISOCABTAGENE MARALEUCEL

DRUG: Lymphodepleting chemotherapy

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R...
This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).

DRUG: ONO-7018

DRUG: ONO-7018

CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects...

BIOLOGICAL: CART123 cells; cyclophosphamide; fludarabine

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndro...
The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS.

DRUG: KER-050

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

OTHER: Electronic Health Record Review

OTHER: Photography

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-po...

DRUG: AFM13

DRUG: AB-101

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Interleukin-2

Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical H...
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentu...

DRUG: Brentuximab Vedotin

BIOLOGICAL: Nivolumab

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

DRUG: Ruxolitinib Oral Tablet [Jakafi]

DRUG: Lenalidomide

DRUG: Methylprednisolone

Umbilical Cord Blood Transplantation From Unrelated Donors
This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

RADIATION: Total Body Irradiation 1200 cGy

RADIATION: Total Body Irradiation 200 cGy

DRUG: Cyclophosphamide

DRUG: Mesna

PROCEDURE: Cord Blood Infusion

DRUG: Busulfan

DRUG: Fludarabine

DRUG: Melphalan

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count,...

DRUG: Hyperbaric oxygen

A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thr...
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy...

DRUG: Selinexor 60 mg

DRUG: Selinexor 40 mg

DRUG: Ruxolitinib

DRUG: Pacritinib

DRUG: Momelotinib

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for th...
This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following lymphodepletion in treating pati...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Leukapheresis

PROCEDURE: Lymphodepletion Therapy

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Positron Emission Tomography

PROCEDURE: X-Ray Imaging

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).

DRUG: Itacitinib

BIOLOGICAL: Chimeric antigen receptor (CAR) T-cell therapy

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body...

DRUG: CAR138 T Cells

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT ...
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (m...

DRUG: Tirabrutinib

DRUG: Tirabrutinib

DRUG: Tirabrutinib

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoi...
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Dual X-ray Absorptiometry

DRUG: Tegavivint

PROCEDURE: X-Ray Imaging

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoieti...
Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant (allo-HCT). However, the complete remission (CR) rates and l...

DRUG: CIML NK Cell Infusion

PROCEDURE: CD3+ T Cell Product Infusion

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and t...

DRUG: Mogamulizumab

RADIATION: LD TSEBT

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic S...
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory)...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

DRUG: UAE Inhibitor TAK-243

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Mye...

DRUG: TL-895

DRUG: Placebo

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Sy...
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

DRUG: Gemcitabine

DRUG: Pembrolizumab

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell...
This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) an...

BIOLOGICAL: AUTO1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR...
Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy a...

BIOLOGICAL: obinutuzumab

DRUG: prednisone

DRUG: Revlimid

BIOLOGICAL: Polatuzumab

DRUG: ibrutinib

DRUG: venetoclax

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).

DRUG: Lenalidomide

DRUG: Luspatercept

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in diff...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Pha...

DRUG: Iptacopan

DEC-C and Thioguanine for R/R AML
The purpose of this study is to find out if oral decitabine-cedazuridine (Inqovi®) is effective, safe, and able to be tolerated without severe side effects when given with thioguanine (Tabloid®) in patients with acute myeloid leukemia (AML) whose dis...

DRUG: Thioguanine (Tabloid ®)

DRUG: DecitabineCedazuridine (Inqovi ®)

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Ly...
This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chr...

DRUG: Acalabrutinib

BIOLOGICAL: Durvalumab

DRUG: Venetoclax

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML Afte...
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte ant...

BIOLOGICAL: VCAR33

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-A...
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy

DRUG: Tecartus

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patien...
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to ...

DRUG: Elranatamab

DRUG: Lenalidomide

DRUG: Plerixafor

DRUG: Melphalan

DRUG: Busulfan

DRUG: G-CSF

PROCEDURE: Stem cell transplant

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapie...
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatm...

DRUG: ABBV-383

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Elotuzumab

DRUG: Selinexor

DRUG: Bortezomib

DRUG: Dexamethasone

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myelo...
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma

DRUG: CLN-619

Study of REM-422 in Patients with AML or Higher Risk MDS
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

DRUG: REM-422

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Che...
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of partici...

DRUG: Blinatumomab

DRUG: Low-intensity chemotherapy regimen

DRUG: SOC chemotherapy regimen

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL0...
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kina...

DRUG: Asciminib 40 MG

DRUG: Asciminib 40 MG Twice Daily

DRUG: Asciminib 80 MG daily

DRUG: Imatinib

DRUG: Nilotinib

DRUG: Dasatinib

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With ...
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. T...

BIOLOGICAL: Zilovertamab vedotin

BIOLOGICAL: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

DRUG: Bendamustine

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-labe...

BIOLOGICAL: QXL138AM Injection every 2 weeks by IV Infusion

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple ...
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the ef...

BIOLOGICAL: CB-011

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or ...

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Dexamethasone

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and...
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Sometimes these transplants cause serious side effects,...

DRUG: Melphalan

DRUG: Sirolimus

RADIATION: Total Body Irradiation (TBI)

DRUG: Cyclophosphamide

DRUG: Mycophenolate Mofeti

DRUG: Fludarabine

PROCEDURE: Allogeneic HSCT

DRUG: Mesna

DRUG: Filgrastim

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People Wit...
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment f...

DRUG: Venetoclax monotherapy

DRUG: Venetoclax with anti CD20 monoclonal antibody

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two tar...

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR Aft...
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will a...

DRUG: Loncastuximab Tesirine

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal res...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Golcadomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of Hi...
This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendam...

DRUG: Bendamustine

DRUG: Rituximab

DRUG: Tazemetostat

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patient...
This open-label, single arm phase 1/1b trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell N...

DRUG: CD19x22 CAR T Cells

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory M...
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

BIOLOGICAL: STI-1492

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

DRUG: Zanubrutinib

DRUG: Rituximab

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or H...
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subje...

DRUG: HCB101

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose ...

DRUG: APG 2575 ramp up arm

Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

DRUG: SGR-1505

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Vene...
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and chan...

DRUG: Venetoclax

DRUG: Acalabrutinib

DRUG: Obinutuzumab

Pirtobrutinib and Venetoclax with MRD Detection for Previously Untreated Chronic Lymphocytic Leukemi...
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

DRUG: Pirtobrutinib

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Biopsy

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs:...

DRUG: CD79b-19 CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia. PRIMARY OBJECTIVE: I. To...

BIOLOGICAL: Universal Donor Natural Killer Cells

Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to N...

DRUG: Ketorolac

DRUG: Normal saline

DRUG: Acetaminophen

DRUG: Oxycodone Acetaminophen

DRUG: Morphine

DRUG: Hydrocodone/Acetaminophen

DRUG: Oxycodone

Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find t...

DRUG: IMT-009

COMBINATION_PRODUCT: Fruquintinib

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in ...
This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclona...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Tazemetostat

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the...

DRUG: Balstilimab

DRUG: Botensilimab

DRUG: Liposomal Doxorubicin

DEVICE: Sonocloud-9 (SC-9)

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or...
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

DRUG: BMS-986497

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhib...

DRUG: Acalabrutinib

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSC...
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive...

DRUG: Tagraxofusp

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Ly...
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab ...
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuz...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Blinatumomab

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Prednisone

DRUG: Pegfilgrastim

DRUG: Inotuzumab ozogamicin

DRUG: Rituximab

DRUG: Dexamethasone

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their ly...

DRUG: Obinutuzumab

DRUG: Glofitamab

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chem...
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and de...

PROCEDURE: AutoSCT OR CAR T-cell Therapy

DRUG: GDP

DRUG: Epcoritamab

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Dif...
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastux...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

BIOLOGICAL: Loncastuximab Tesirine

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

A Long-term Extension Study of PCI-32765 (Ibrutinib)
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed ac...

DRUG: Ibrutinib

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 ...
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose e...

DRUG: AG-120

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Le...
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will either be studied as: * Monotherapy, or * Combination therapy: * epcoritamab + vene...

BIOLOGICAL: Epcoritamab

BIOLOGICAL: Epcoritamab

DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

DRUG: Venetoclax

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relap...
This phase I/II trial studies the side effects and how well cladribine, idarubicin, cytarabine, and quizartinib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that is newly diagnosed, has come back (relaps...

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Idarubicin

DRUG: Quizartinib

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or W...
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS...

DRUG: LYT-200

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Decitabine

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venet...

DRUG: Venetoclax

DRUG: Tazemetostat

Erector Spinae Block for Thoracic Surgery
The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.

DRUG: ESB Thoracic

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies o...
The primary goal of this Phase 1 study is to characterize the safety and tolerability of DZ-002 and establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of DZ-002 administered on a weekly schedule in patients with solid ...

DRUG: DZ-002

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVE...
To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.

DRUG: Azacitidine

DRUG: Venetoclax

DRUG: NK Cells

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

DRUG: BMF-500

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height a...

OTHER: Pharmacokinetics

OTHER: Pharmacokinetics

18F-Fluciclovine PET/CT in Multiple Myeloma
Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning di...

DRUG: 18F-fluciclovine injection

PROCEDURE: 18F-FDG PET/CT

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromos...
This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respo...

BIOLOGICAL: Blinatumomab

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Ponatinib

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid...
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. The study will evaluate safety in this patient popu...

BIOLOGICAL: CD4CAR

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic ...
This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not ...

DRUG: Akt/ERK Inhibitor ONC201

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, a...

DRUG: FT522

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lympho...
This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back after treatment (rel...

DRUG: Venetoclax

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy...
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many ...

PROCEDURE: Biospecimen Collection

OTHER: cfDNA or ctDNA Measurement

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Nivolumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Relatlimab

Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic...
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking som...

DRUG: Acalabrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Obinutuzumab

OTHER: Patient Observation

OTHER: Quality-of-Life Assessment

NTX-301 in MDS/AML
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.

DRUG: NTX-301

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large...
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agon...

DRUG: NKTR-255 at 1.5 µg/kg

DRUG: NKTR-255 at 3.0 μg/kg

DRUG: NKTR-255 at 3.0/6.0 μg/kg

OTHER: Placebo Comparator

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.

DRUG: Talazoparib

DRUG: Decitabine

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Ane...
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependen...

DRUG: INCB000928

DRUG: ruxolitinib

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

DRUG: Clofarabine

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Cyclosporine-A

DRUG: Mycophenolate Mofetil

BIOLOGICAL: Cord Blood Graft

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Ce...
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in diff...

DRUG: AKR1C3-activated Prodrug OBI-3424

MBG453 in Lower Risk MDS
This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.

DRUG: MBG453

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multipl...
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This...

DRUG: Daratumumab SC

DRUG: Clarithromycin

DRUG: Pomalidomide

DRUG: Dexamethasone

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard fron...

DRUG: Acalabrutinib

BIOLOGICAL: Rituximab

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease ...
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persis...

DRUG: DEC-C

DEVICE: MyeloSeq-HD

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refra...
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

BIOLOGICAL: GC012F (AZD0120)

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide,...
This phase I trial studies the best dose and side effects of M3814 when given in combination with mitoxantrone, etoposide, and cytarabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiogram Recording

DRUG: Etoposide Phosphate

DRUG: Mitoxantrone Hydrochloride

PROCEDURE: Multigated Acquisition Scan

DRUG: Peposertib

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. T...

RADIATION: Involved site radiotherapy

DRUG: Doxorubicin

DRUG: Bleomycin

DRUG: Brentuximab vedotin

DRUG: Vinblastine

DRUG: Dacarbazine

DRUG: Haematopoietic growth factor

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixe...

DRUG: Vyxeos

DRUG: Gemtuzumab Ozogamicin

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or co...

DRUG: ATL-RIC

DRUG: mRIC

PROCEDURE: allo HCT

DRUG: RIC

DRUG: GVHD prophylaxis

DRUG: IOC

Rifaximin in Patients With Monoclonal Gammopathy
This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

DRUG: Rifaximin

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patien...

DRUG: JNJ-90009530

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin...
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical ...

DRUG: AB-101

DRUG: Rituximab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the ...
Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells. Object...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Anti-KRAS G12V mTCR PBL

DRUG: Aldesleukin

TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large ...
This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Ontorpacept

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Maplirpacept

PROCEDURE: Biopsy

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects ...
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

DRUG: DPX-Survivac

DRUG: Pembrolizumab

DRUG: CPA

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each c...

DRUG: Pembrolizumab

DRUG: Mogamulizumab

Study of Radiolabeled Revumenib in Adults With Acute Leukemia
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.

DRUG: Revumenib

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Melphalan

DRUG: Rituximab

DRUG: Levetiracetam

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neopla...
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell grow...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Methylprednisolone

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tagraxofusp-erzs

DRUG: Venetoclax

DRUG: Vincristine

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

DRUG: BGB-16673

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-deriv...
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.

DRUG: Rimiducid

DRUG: TROP2-CAR-NK Cells

DRUG: Fludarabine phosphate

DRUG: Cyclophosphamide

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regime...
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also allow partic...

DRUG: Mosunetuzumab

DRUG: Tocilizumab

DRUG: Venetoclax

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World...
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

OTHER: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal

DRUG: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the ...

DRUG: AC676

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic M...
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

DRUG: Asciminib

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May...
The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of high-risk monoclonal gammopathy of undetermined significance (HR-MGUS) and non high-risk smoldering multiple myeloma...

DRUG: Linvoseltamab

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

DRUG: Ruxolitinib

Autologous Dendritic Cell Vaccine in Kidney Cancer
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.

BIOLOGICAL: Autologous alpha-DC1/TBVA vaccine

DRUG: Cabozantinib

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-...

BIOLOGICAL: COVID-19 Vaccine

OTHER: Diagnostic Laboratory Biomarker Analysis

BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Ch...
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and...

BIOLOGICAL: CD4CAR

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor ...
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene tr...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Aldesleukin

BIOLOGICAL: Anti-hCD70 CAR transduced PBL

A Phase 1 with Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin...
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study wil...

DRUG: Belantamab mafodotin

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators h...

DRUG: Mosunetuzumab

DRUG: Tazemetostat Pill

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymph...
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination wi...

DRUG: CC-220

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: CC-99282

DRUG: Polatuzumab vedotin

DRUG: Rituximab

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients...
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously ...

DRUG: Zanubrutinib

BIOLOGICAL: Rituximab

OTHER: Patient Observation

PROCEDURE: Bone Marrow Biopsy

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Esophagogastroduodenoscopy

PROCEDURE: Colonoscopy

PROCEDURE: Biospecimen Collection

OTHER: Questionnaire Administration

Ziftomenib Maintenance Post Allo-HCT
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study pla...

DRUG: Ziftomenib

A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Partic...
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or...

DRUG: KQB198

DRUG: Dasatinib

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab ...
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymp...

DRUG: Odronextamab

DRUG: Lenalidomide

DRUG: Rituximab

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Follow...
This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patie...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Myeloablative Conditioning

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma...
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not ...

DRUG: Soquelitinib

DRUG: Belinostat

DRUG: Pralatrexate

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclist...
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minima...

DRUG: Cilta-cel

DRUG: Talquetamab

DRUG: Daratumumab

DRUG: Teclistamab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Cyclophosphamide

DRUG: Fludarabine

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tc...
This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with primary central nervous system (CNS) lymphoma. CAR T cell therapy ...

PROCEDURE: Aspiration

PROCEDURE: Biospecimen Collection

PROCEDURE: Catheterization

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relap...
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as deter...

DRUG: Zanubrutinib

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Obinutuzumab

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the bes...

DRUG: GDX012

DRUG: Chemotherapy Agents

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin ...
To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides

DRUG: Brentuximab vedotin

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase I...

DRUG: Inotuzumab Ozogamicin

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

DRUG: CK0804

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MC...
To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

DRUG: Rituximab

DRUG: Pirtobrutinib

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodyspla...
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to l...

DRUG: Edetate Calcium Disodium

DIETARY_SUPPLEMENT: Multivitamin

DRUG: Succimer

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for New...
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

PROCEDURE: Electrocardiography

PROCEDURE: Lumbar Puncture

DRUG: Mesna

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Ponatinib Hydrochloride

DRUG: Prednisone

DRUG: Vincristine Sulfate

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against...
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prednisolone

A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

DRUG: NX-1607

DRUG: Paclitaxel

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymp...
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

DRUG: ATG-101

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and...
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in ...

DRUG: Talquetamab

DRUG: Daratumumab

DRUG: Pomalidomide

DRUG: Dexamethasone

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-...
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid...

BIOLOGICAL: tabelecleucel

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologo...
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

DRUG: Iberdomide

DRUG: Lenalidomide

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypome...
A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to exceed 10 days if postponement is required to all...

DRUG: Tagraxofusp (Cycles 1-2)

DRUG: Azacitidine

DRUG: Tagraxofusp (Cycles 3-12)

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After T...
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplan...

DRUG: Elranatamab

DRUG: Lenalidomide

DRUG: Lenalidomide

DRUG: Elranatamab

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple My...
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Iberdomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

DRUG: Teclistamab

CAR-T Followed by Bispecific Antibodies
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who ...

DRUG: mosunetuzumab

DRUG: glofitamab

DRUG: obinutuzumab

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Me...
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

DRUG: Venetoclax

DRUG: Revumenib

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenou...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gem...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Oxaliplatin

DRUG: Gemcitabine

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously T...
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected...

DRUG: JNJ-79635322

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

BIOLOGICAL: CD371-specific/YSNVz/I-18 CAR T cells

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patie...
This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

BIOLOGICAL: Filgrastim

OTHER: Laboratory Biomarker Analysis

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Tacrolimus

RADIATION: Total Marrow Irradiation

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

DRUG: SGR-2921

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cance...
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.

BIOLOGICAL: SENTI-202

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

DRUG: Fenretinide

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are inf...

BIOLOGICAL: Autologous MUC1-activated T-cells

DRUG: Bendamustine

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab i...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic ...

DRUG: Epcoritamab

DRUG: Lenalidomide

DRUG: Ibrutinib

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride [HCl]

DRUG: Prednisone

DRUG: Polatuzumab Vedotin

DRUG: Venetoclax

DRUG: CC-99282

DRUG: Pirtobrutinib

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative D...
This study will test polatuzumab vedotin in combination with rituximab in patients with treatment-naïve CD20-positive post-transplant lymphoproliferative disorder (PTLD) based on the established efficacy of polatuzumab vedotin in B-cell lymphomas and...

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: CHP

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid...
This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may ...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

DRUG: Iadademstat

PROCEDURE: Multigated Acquisition Scan

OTHER: Questionnaire Administration

DRUG: Venetoclax

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myel...
This phase 2 study aims to confirm the efficacy seen in the prior phase 1 trial, and further contribute to this effort through the collection of leukemia cells pre- and post- in vivo IFN-γ therapy. As in the previously conducted phase 1 trial, this t...

DRUG: Interferon gamma-1b

BIOLOGICAL: Donor Leukocyte Infusion (DLI)

A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric...

DRUG: Fludarabine (Conditional therapy)

DRUG: Cyclophosphamide Monohydrate (Conditional therapy)

DRUG: firi-cel (Experimental drug)

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positi...
This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are...

DRUG: Dasatinib

DRUG: Decitabine and Cedazuridine

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

DRUG: Venetoclax

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexametha...

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Ixazomib

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Pha...

DRUG: Bleximenib

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Re...
This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back o...

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Idarubicin

BIOLOGICAL: Pegfilgrastim

DRUG: Venetoclax

DALY II USA/ MB-CART2019.1 for DLBCL
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after rece...

BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after inductio...

DRUG: Iberdomide

DRUG: Daratumumab

DRUG: Dexamethasone

DRUG: Carfilzomib

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Di...
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers o...

DRUG: Rituximab Prednisone

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.

DRUG: Luspatercept

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochlor...
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelo...

DRUG: Cytarabine

DRUG: Decitabine

BIOLOGICAL: Filgrastim-sndz

DRUG: Fludarabine Phosphate

DRUG: Gemtuzumab Ozogamicin

DRUG: Idarubicin

OTHER: Laboratory Biomarker Analysis

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulati...

DRUG: Carfilzomib

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Granulocyte Colony-Stimulating Factor

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Background: Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers thi...

DRUG: binimetinib

DRUG: Encorafenib

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

DRUG: ISB 1442 SC injection escalating doses

DRUG: ISB 1442 SC injection at RP2D

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Ly...
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.

RADIATION: Ultra Low Dose 4 Gy Radiation

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractor...
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lin...

DRUG: Revumenib

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: intrathecal (IT) chemotherapy

DRUG: Cytarabine

DRUG: Methotrexate

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adu...
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

DRUG: JV-213

PROCEDURE: Leukapheresis

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukem...
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or ...

DRUG: Bortezomib

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Etoposide

BIOLOGICAL: Ofatumumab

BIOLOGICAL: Pegfilgrastim

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate Liposome

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is...

DRUG: Bomedemstat

DRUG: Hydroxyurea

DRUG: Bomedemstat placebo

DRUG: Hydroxyurea placebo

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation fo...
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating patients with high-risk ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Basiliximab

DRUG: Fludarabine Phosphate

DRUG: Indium In 111-DOTA-Basiliximab

DRUG: Melphalan

BIOLOGICAL: Palifermin

RADIATION: Total Lymphoid Irradiation

RADIATION: Total Marrow Irradiation

BIOLOGICAL: Yttrium Y 90 Basiliximab

Inqovi Maintenance Therapy in Myeloid Neoplasms
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. * This research study involve...

DRUG: Inqovi

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic...
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies

BIOLOGICAL: CTX131

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.

DRUG: Givinostat

DRUG: Hydroxyurea

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

DRUG: Tasquinimod

DRUG: IRd chemotherapy

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnos...
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed...

DRUG: Gilteritinib

DRUG: Venetoclax

DRUG: Azacitidine

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy a...

DRUG: Asciminib

DRUG: Ascimininb + Nilotinib

DRUG: Asciminib + Imatinib

DRUG: Asciminib + Dasatinib

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Sourc...

DRUG: Danvatirsen

COMBINATION_PRODUCT: Danvatirsen + Venetoclax

CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will...

BIOLOGICAL: CD4CAR

Dietary and Topical Magnesium Replacement or Supplementation in Patients with Lymphoma
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium an...

DRUG: Magnesium Chloride-based Lotion

OTHER: Quality-of-Life Assessment

BEHAVIORAL: Special Diet Therapy

Lurbinectedin in FET-Fused Tumors
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

DRUG: Lurbinectedin

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma. Polatuzumab vedotin is a m...

DRUG: Prednisone

DRUG: Prednisolone

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Polatuzumab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
This research study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) which has come back, or ma...

BIOLOGICAL: MultiTAA-specific T cells

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Mult...
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists o...

DRUG: APG-2575+ Pd

DRUG: APG-2575 + DRd

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous Syst...
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or r...

DRUG: Pemetrexed

DRUG: Zanubrutinib

PROCEDURE: Autologous Stem Cell Transplant (ASCT)

RADIATION: Whole Brain Radiation Therapy (WBRT)

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refr...
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy wi...

BIOLOGICAL: Blinatumomab

BIOLOGICAL: Inotuzumab Ozogamicin

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin ly...

DRUG: DOC Group B

DRUG: Pv-COMRAD 1 and 2 Group B

DRUG: Pv-R-CYM 1 and 2 Group B

DRUG: DOC Group C

DRUG: MAD CPR 1 and 2

DRUG: Pv-R CYVE 1 and 2

DRUG: Pv-R CYVE-MTX 1 and 2

DRUG: MAD CP

DRUG: Pv-Cytarabine/etoposide

DRUG: AD CP

DRUG: Bv-AVD-R 1 and 2: COHORT IIa

DRUG: Bv-NVD-R, Cycle 1-2

DRUG: Bv-NVD-R, Cycle 1-4 SER

DRUG: Bv-AVD-R

DRUG: Bv-NVD-R, Cycle 1-4 RER

DRUG: Bv-NAVD-R, Cycle 1-2

RADIATION: Involved Site Radiation Therapy

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Ly...
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed ...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

DRUG: Zanubrutinib

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

BIOLOGICAL: BAFFR-CAR T cells

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Ris...
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune ...

DRUG: Dexamethasone

DRUG: Iberdomide Hydrochloride

OTHER: Quality-of-Life Assessment

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemi...
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.

DRUG: Vyxeos

DRUG: Venetoclax

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Conso...
To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving bre...

DRUG: Blinatumomab

DRUG: Inotuzumab Ozogamicin

DRUG: Hyper-CVAD

DRUG: Mini-hyper-CVD

AZD6738 for Patients With Progressive MDS or CMML
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .

DRUG: AZD6738

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

DRUG: brentuximab vedotin

DRUG: brentuximab vedotin

DRUG: brentuximab vedotin

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukem...
This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improv...

DRUG: Eltanexor

DRUG: Venetoclax

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Biospecimen Collection

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment o...

BIOLOGICAL: CD19-CAR(Mem) T-cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

DEVICE: CliniMACS

PROCEDURE: Leukapheresis

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myel...
Multiple myeloma (MM) is a malignancy characterized by uncontrolled proliferation of plasma cells for which there is an urgent and unmet need to develop new, effective therapeutics. Onconova Therapeutics has developed a first-in-class oral inhibitor ...

DRUG: ON 123300

DRUG: Dexamethasone

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymp...
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: anti-CD19 CAR-T cells

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patie...
This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have ...

DRUG: Fludarabine Phosphate

DRUG: Melphalan

RADIATION: Intensity-Modulated Radiation Therapy

RADIATION: Total Marrow Irradiation

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Peripheral Blood Stem Cell Transplantation

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Laboratory Biomarker Analysis

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ H...
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

DRUG: SYNCAR-001

DRUG: STK-009

DRUG: Cyclophosphamide

DRUG: Fludarabine

Epcoritamab in Previously Treated WM
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)

DRUG: Epcoritamab

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cel...
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressi...

DRUG: cemiplimab

DRUG: odronextamab

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

DRUG: Pirtobrutinib

DRUG: Obinutuzumab

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Pat...
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-eligible pati...

DRUG: Acalabrutinib

DRUG: Bortezomib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and s...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Busulfan

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Melphalan

DRUG: Methotrexate

DRUG: Mycophenolate Mofetil

DRUG: Ruxolitinib

DRUG: Tacrolimus

RADIATION: Total-Body Irradiation

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Ultrasound Imaging

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

BIOLOGICAL: CD19x22 CAR T

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3...

DRUG: Decitabine

BIOLOGICAL: Tagraxofusp-erzs

Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and...

DRUG: Selinexor

DRUG: Selinexor

OTHER: Placebo

DRUG: Ruxolitinib

9-ING-41 in Pediatric Patients with Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

DRUG: 9-ING-41

DRUG: Irinotecan

DRUG: Temozolomide

DRUG: Cyclophosphamide

DRUG: Topotecan

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hemato...
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

DRUG: 1A46 Injection

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after trea...

BIOLOGICAL: EBV-specific T cells: A

BIOLOGICAL: EBV-specific T cells: B

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cem...
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy ...

DRUG: ONM-501

DRUG: Cemiplimab

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or P...
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

DRUG: Curcumin plus Piperine

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.

BIOLOGICAL: bbT369

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide fo...
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myelom...
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists o...

DRUG: Isatuximab (for run-in portion)

DRUG: Isatuximab (for expansion)

DRUG: Pomalidomide

DRUG: Elotuzumab

DRUG: Dexamethasone

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Ce...
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Tocilizumab

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Le...
This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refrac...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Gilteritinib

DRUG: Revumenib

Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurr...
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial we will implant a novel device with 9 ultrasound emitters allowing to t...

DEVICE: Sonication for opening of blood-brain barrier

DRUG: Chemotherapy, albumin-bound paclitaxel

DRUG: Chemotherapy, carboplatin

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants...
This is a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or adult participants with CD...

BIOLOGICAL: SAR443579

DRUG: venetoclax

DRUG: azacitidine

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in P...
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in ...

DRUG: Golcadomide

DRUG: Placebo

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transp...
This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma intending to pursu...

DRUG: Mosunetuzumab

DRUG: DHAX

DRUG: ICE

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous...
The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologou...

DRUG: Siltuximab

DRUG: Melphalan

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinet...

DRUG: Senza5 CART5

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxo...
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated C...

DRUG: Glofitamab

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutatio...
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a ...

DRUG: Iadademstat

DRUG: Gilteritinib Oral Tablet

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)\] in the treatment of acute myeloid leukemia (AML) that has n...

DRUG: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic L...
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 pha...

DRUG: Linvoseltamab

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer c...

DRUG: Dara-VRd intensification, Dara-R maintenance

DRUG: AHCT intensification, Dara-R maintenance

DRUG: AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance

DRUG: AHCT intensification, Dara-R consolidation, Dara-R maintenance

DRUG: Dara-VRd induction

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Ho...
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. O...

BIOLOGICAL: Nivolumab

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lym...
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory)...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

DRUG: Venetoclax

A Safety and Tolerability Study of Jaktinib
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

DRUG: Jaktinib Hydrochloride Tablet

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being do...

RADIATION: Adaptive Bridging Radiation Therapy (ABRT)

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through th...
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

DRUG: ABBV-101

Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants Wi...
Background: People with GATA2 deficiency have a mutation on the GATA2 gene. This gene affects immune function. People with this disease are prone to serious infections; in time, they may develop blood cancers. A hematopoietic stem cell (HSC) transpl...

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

DRUG: Post-Transplant Cyclophosphamide

RADIATION: Total Body Irradiation

PROCEDURE: Hematopoietic Cell Transplant

DRUG: JSP191

DRUG: Cyclophosphamide

DRUG: Fludarabine

Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Ch...
This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block t...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

DRUG: pembrolizumab

DRUG: gemcitabine

DRUG: vinorelbine

DRUG: liposomal doxorubicin

PROCEDURE: Stem cell mobilization and collection

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may s...

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

DRUG: Methotrexate

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

PROCEDURE: Ultrasound Imaging

SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
This is a phase Ia/Ib, first-in-Human, open-Label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of SG2501 in subjects...

DRUG: SG2501

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomon...
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML p...

DRUG: Trametinib

DRUG: Azacitidine

DRUG: Fludarabine

DRUG: Cytarabine

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Pos...
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lympho...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin

PROCEDURE: Echocardiography

DRUG: Etoposide

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

DRUG: Prednisone

DRUG: Vincristine

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow ...
Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to nee...

DRUG: RIC

DRUG: GVHD prophylaxis

PROCEDURE: allo HCT

DRUG: Plerixafor

DRUG: Maraviroc

Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patie...

DRUG: Tulmimetostat

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute M...
This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Dual-Energy Computed Tomography

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Magnetic Resonance Imaging

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total Marrow and Lymphoid Irradiation

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grad...
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refra...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leu...

BIOLOGICAL: Rapcabtagene autoleucel single agent

DRUG: Ibrutinib

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemo...
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal ant...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Mercaptopurine

DRUG: Doxorubicin

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed ...
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, ...

OTHER: Clinical Observation

DRUG: Crizotinib

OTHER: Laboratory Biomarker Analysis

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refra...
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

DRUG: AZD3470

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Ly...
This phase II trial is to evaluate the effects of acalabrutinib in combination with venetoclax in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that does not respond to treatment (refractory) or that has come back ...

DRUG: Acalabrutinib

DRUG: Venetoclax

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

DRUG: Daunorubicin

PROCEDURE: Electrocardiography

DRUG: Pemigatinib

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
The goal of this study is to test SIRPant-M, an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being te...

BIOLOGICAL: SIRPant-M

RADIATION: External-beam radiotherapy (XRT)

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in...
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatm...

DRUG: Subcutaneous (SC) ABBV-383

DRUG: Intravenous (IV) ABBV-383

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patie...
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

DRUG: 131-I Apamistamab

BIOLOGICAL: CAR T-cell

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple...
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

DRUG: Elotuzumab

DRUG: Belantamab mafodotin

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determin...
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy follow...

BIOLOGICAL: CYAD-02

DRUG: ENDOXAN

DRUG: Fludara

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone...
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced inten...

OTHER: Ossium HPC Marrow, Bone Marrow Transplant

OTHER: Pre-transplant conditioning - Myeloablative (MAC)

OTHER: Pre-transplant conditioning - Reduced Intensity (RIC)

OTHER: Post-transplant treatment

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and...
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic an...

DRUG: EAGD T-cell infusion (Phase I)

DRUG: EAGD T-cell infusion (Expansion)

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 ...
This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Enasidenib

DRUG: Enasidenib Mesylate

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Ste...
The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn...

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Bendamustine

BIOLOGICAL: Filgrastim-sndz

DRUG: Fludarabine

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Melphalan

PROCEDURE: Peripheral Blood Stem Cell Transplantation

BIOLOGICAL: Rituximab

DRUG: Tacrolimus

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG...

COMBINATION_PRODUCT: BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2

Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutatio...
This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blockin...

DRUG: Enasidenib Mesylate

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who ...

DRUG: Fludarabine

DRUG: Cytarabine

DRUG: Gemtuzumab Ozogamicin

DRUG: Azacitidine

DRUG: Venetoclax

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smol...
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways ...

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve...
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: * Venetoclax * Daunorubicin * Cytarabine

DRUG: Venetoclax

DRUG: Daunorubicin

DRUG: Cytarabine

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

DRUG: Teclistamab

DRUG: Talquetamab

DRUG: Tocilizumab

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

DRUG: STP938

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer ...
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impair...

DRUG: Tazemetostat

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific A...
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to ch...

DRUG: Palbociclib

DRUG: Sunitinib

DRUG: Temsirolimus

DRUG: Trastuzumab and Pertuzumab

DRUG: Vemurafenib and Cobimetinib

DRUG: Regorafenib

DRUG: Olaparib

DRUG: Pembrolizumab

DRUG: Nivolumab and Ipilimumab

DRUG: Abemaciclib

DRUG: Talazoparib

DRUG: Atezolizumab and PHESGO

DRUG: Atezolizumab and Talazoparib

DRUG: Entrectinib

DRUG: Larotrectinib

DRUG: Tucatinib plus Trastuzumab Subcutaneous (SC)

DRUG: Futibatinib

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating W...
To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Venetoclax

DRUG: Azacitidine

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with rela...

BIOLOGICAL: JNJ-90014496

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid L...
This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or elderly patients with newly diagnosed acute m...

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Ha...
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subje...

DRUG: Navtemadlin

DRUG: Navtemadlin placebo

DRUG: Ruxolitinib

High Dose Ascorbic Acid for Plasma Cell Disorders
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.

OTHER: Ascorbate

DRUG: Melphalan

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab...
The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed me...

DRUG: maplirpacept (PF-07901801)

DRUG: Glofitamab

DRUG: Obinutuzumab

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymph...
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of ca...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Obinutuzumab

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatme...
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned pembrolizumab monothe...

DEVICE: Blood Brain Barrier Disruption - Oncology

DRUG: Pembrolizumab

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancie...

DRUG: L-Bcl-2 antisense oligonucleotide

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Eps...
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

DRUG: Nanatinostat in combination with valganciclovir

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Media...
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

DRUG: Etoposide Phosphate

BIOLOGICAL: Filgrastim

PROCEDURE: Lumbar Puncture

BIOLOGICAL: Nivolumab

BIOLOGICAL: Pegfilgrastim

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

DRUG: Prednisone

RADIATION: Radiation Therapy

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

DRUG: Vincristine Sulfate

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lym...
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

GENETIC: CB-010

DRUG: Cyclophosphamide

DRUG: Fludarabine

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come b...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: CD70-CAR T cell infusion (Autologous)

DRUG: Mesna

Chimeric Antigen Receptor T-cells for the Treatment of AML Expressing CLL-1 Antigen
Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two d...

BIOLOGICAL: CLL-1.CAR T cells

huCART19-IL18 in CD19+ Cancers
The purpose of this study is to find the maximum dose of huCART19-IL18 cells that is safe for use in humans with CD19+ cancers.

BIOLOGICAL: huCART19-IL18

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemi...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

BIOLOGICAL: Ipilimumab

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

DRUG: PAXALISIB

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplast...
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1 (Dose Es...

DRUG: BH-30236

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted...
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is...

DEVICE: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in...

BIOLOGICAL: PIT565

Photopheresis in Early-stage Mycosis Fungoides
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. H...

DRUG: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis

DEVICE: THERAKOS® CELLEX photopheresis system

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Mono...
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. ...

DRUG: Cyclophosphamide

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Daratumumab

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking som...

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Selinexor

Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

DRUG: Epcoritamab

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

DRUG: Docirbrutinib

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory...
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisati...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: JCAR017

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After I...
This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a comb...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Ac...
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood ...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Tacrolimus

BIOLOGICAL: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs

DRUG: Methotrexate

DRUG: Cyclophosphamide

BIOLOGICAL: Peripheral Blood Stem Cell

DRUG: Cyclosporine

DRUG: Sirolimus

DRUG: Busulfan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Biospecimen Collection

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neu...
Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\<100 neu...

DRUG: Eravacycline

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or R...
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

DRUG: Axicabtagene Ciloleucel

Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can r...

DRUG: Ritlecitinib

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrom...
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

DRUG: CLN-049

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

DRUG: CFI-400945

DRUG: Azacitidine

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called...

BIOLOGICAL: Loncastuximab Tesirine

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic ...

RADIATION: Bridging radiation therapy

BIOLOGICAL: Liso-cel

RADIATION: Post-infusion radiation

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuz...
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a sing...

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Tocilizumab

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The obj...

PROCEDURE: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of ...
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refr...

OTHER: Cellular Therapy

DRUG: Ruxolitinib

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: ...

DRUG: Pembrolizumab

DRUG: Methotrexate

DRUG: Temozolomide

DRUG: Rituximab

Study of IMPT-314 in R/R Aggressive B-cell NHL
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three co...

DRUG: IMPT-314

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Sign...
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DIETARY_SUPPLEMENT: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement

DIETARY_SUPPLEMENT: Piperine Extract (Standardized)

DRUG: Placebo Administration

OTHER: Questionnaire Administration

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Othe...
This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplasti...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Pati...
The purpose of this study is to test the safety and determine the best dose of venetoclax and selinexor when given with chemotherapy drugs in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous...

DRUG: Venetoclax

DRUG: Selinexor

DRUG: Cytarabine

DRUG: Fludarabine

BIOLOGICAL: Filgrastim

DRUG: Methotrexate

DRUG: methotrexate/hydrocortisone/cytarabine

Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (...

DRUG: Ibrutinib

DRUG: Pembrolizumab

DRUG: Rituximab

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematol...
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivoside...

DRUG: Azacitidine

DRUG: Ivosidenib

DRUG: Venetoclax

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currentl...
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three p...

DRUG: Pembrolizumab

DRUG: Standard of Care (SOC)

DRUG: Lenvatinib

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloi...
The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied....

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Decitabine

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First...
This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a typ...

DRUG: Autologous Anti-CD19 CAR-expressing T Lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

OTHER: Questionnaire Administration

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma ...
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously treated with brentuxi...

DRUG: Brentuximab Vedotin

PROCEDURE: Hematopoietic Cell Transplantation

BIOLOGICAL: Nivolumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell ...
This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not re...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Ca...
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

DRUG: Mezigdomide

DRUG: Carfilzomib

DRUG: Dexamethasone

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refra...
This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes

DRUG: Fludarabine Phosphate

PROCEDURE: Leukapheresis

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.

DRUG: Hyperbaric oxygen

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by...

DRUG: Cladribine

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Rituximab

Fludarabine Based RIC for Bone Marrow Failure Syndromes
This is a pilot study to determine whether fludarabine-based reduced intensity conditioning (RIC) regimens facilitate successful donor engraftment of patients with acquired aplastic anemia (AA) and Inherited bone marrow failure (iBMF) syndromes under...

OTHER: MRD-BMT with Fludarabine-based RIC for Acquired AA

OTHER: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia

OTHER: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronida...
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab (MK-3475) following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase (MK-3475A), and to evaluate the objective response rate ...

BIOLOGICAL: Pembrolizumab Coformulated With Hyaluronidase

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Ce...
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder si...

DRUG: Vemurafenib

DRUG: Obinutuzumab

DRUG: Cladribine

DRUG: Rituximab

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute...
With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To...

DRUG: Palbociclib

DRUG: Dexamethasone

DRUG: Bortezomib

DRUG: Doxorubicin

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intrav...
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous a...

DRUG: Epcoritamab

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Prednisone

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Ther...
This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

DRUG: Selinexor

DRUG: Lenalidomide

DRUG: Methylprednisolone

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

DRUG: CPI-0209

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (rel...

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusio...

DRUG: CD22CART infusion

DRUG: Tisagenlecleucel

Pacritinib in CMML
This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who ha...

DRUG: Pacritinib

DRUG: Azacitidine

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multi...
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufactur...

DRUG: Teclistamab

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric ...
To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment gr...

DRUG: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

DRUG: Treg CD34+HSPC (Orca-T)

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Fo...
This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and myelodysplastic syndrome (...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

OTHER: Questionnaire Administration

BIOLOGICAL: Tagraxofusp-erzs

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual d...

GENETIC: cemacabtagene ansegedleucel

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

DEVICE: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Tre...
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

DRUG: Lenalidomide

PROCEDURE: Positron Emission Tomography

DRUG: Prednisone

DRUG: Vincristine Sulfate

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refrac...
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophos...

DRUG: Venetoclax

DRUG: Standard Chemotherapy

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cel...

DRUG: BAFF CAR-T

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy ...
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if ...

BIOLOGICAL: favezelimab/pembrolizumab

DRUG: bendamustine

DRUG: gemcitabine

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the grow...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Etoposide

DRUG: Duvelisib

DRUG: Oral azacitidine

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Pa...
This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high ene...

DRUG: Low Dose Radiation Therapy

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) m...

DEVICE: Alpha Beta T cell depletion

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric...
The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Pl...
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymp...

DRUG: Relatlimab

DRUG: Nivolumab

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mut...
To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.

DRUG: Gilteritinib

DRUG: Momelotinib

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Settin...
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survi...

DRUG: Azacitidine

DRUG: Venetoclax

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignanc...
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL)...

GENETIC: UB-VV111

DRUG: rapamycin

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid ...

DRUG: Bexarotene

RADIATION: Total Skin Electron Beam (TSEB)

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibr...
This initial cohort of this phase II trial studied the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF). The primary risk of using Haplo H...

DRUG: Cyclophosphamide

DRUG: JAK Inhibitor

DRUG: Fludarabine

BIOLOGICAL: Recombinant Granulocyte Colony-Stimulating Factor

DRUG: Melphalan

DRUG: Mycophenolate Mofetil

PROCEDURE: Peripheral Blood Stem Cell Transplantation

DRUG: Tacrolimus

RADIATION: Total-Body Irradiation

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute My...
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in ...

DRUG: CB-012

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Y...
This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lympho...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

OTHER: Questionnaire Administration

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.

RADIATION: Comprehensive Ablative Bridging Irradiation (CABI)

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL ...

DRUG: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow an...
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatm...

BIOLOGICAL: Actinium Ac 225-DOTA-Daratumumab

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Hematopoietic Cell Transplantation

BIOLOGICAL: Indium In 111-DOTA-Daratumumab

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Radionuclide Imaging

PROCEDURE: Single Photon Emission Computed Tomography

DRUG: Sirolimus

DRUG: Tacrolimus

RADIATION: Total Marrow and Lymphoid Irradiation

TriPRIL CAR T Cells in Multiple Myeloma
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. ...

DRUG: TriPRIL CAR T Cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Prednisone

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Cyclophosphamide

DRUG: Obinutuzumab

DRUG: Bendamustine

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatme...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

DRUG: FACT Complex-targeting Curaxin CBL0137

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts...

DRUG: SIM0500

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 ...

DRUG: N803

BIOLOGICAL: CD19t-haNK suspension

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Rituximab

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follic...
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may inter...

DRUG: Ibrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma...
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r)...

DRUG: cemsidomide

DRUG: Dexamethasone Oral

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments...
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

DRUG: Elranatamab + Nirogacestat

DRUG: Elranatamab + lenalidomide + dexamethasone

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of c...

DRUG: Azacitidine

DRUG: Venetoclax

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin S...

DRUG: Canakinumab Injection

DRUG: Darbepoetin Alfa

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participan...
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characteri...

DRUG: JNJ-80948543

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC262

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Dise...
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

OTHER: Discontinue maintenance therapy SOC

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-3...
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd)...

DRUG: ABBV-383

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

DRUG: Nirogacestat

DRUG: Daratumumab

PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors. Participants will have solid tumor or liquid cancer that has spread through the bo...

DRUG: PRO1160

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patient...
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen rece...

DRUG: Selinexor (combination therapy)

DRUG: Selinexor (combination therapy)

DRUG: Selinexor (combination therapy)

DRUG: Placebo matching for Selinexor (combination therapy)

DRUG: Rituximab (combination therapy)

DRUG: Rituximab (combination therapy)

DRUG: Gemcitabine (combination therapy)

DRUG: Dexamethasone (combination therapy)

DRUG: Cisplatin (combination therapy)

DRUG: Selinexor (continuous therapy)

DRUG: Placebo matching for Selinexor (continuous therapy)

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal...
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin ...

BIOLOGICAL: Belantamab Mafodotin

DRUG: Lenalidomide

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneall...
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.

DRUG: TROP2-CAR-NK

DRUG: Cyclophosphamide

DRUG: Fludarabine

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid L...
This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytar...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Quizartinib

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.

DRUG: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)

DRUG: Calaspargase Pegol

DRUG: Rituximab

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).

DRUG: CPX-351

DRUG: MHA

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells see...

BIOLOGICAL: TAA-specific CTLs

BIOLOGICAL: TAA-specific CTLs- fixed dose

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib h...

DRUG: Acalabrutinib

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia. Our project will assess the feasibility and...

BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

DRUG: NX-5948

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalab...

DRUG: Venetoclax

DRUG: Obinutuzumab

DRUG: Acalabrutinib

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinic...

DRUG: Duvelisib

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks f...

DRUG: Cobimetinib

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory F...
This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib in treating patients with FLT3-mutated acute myeloid leukemia that is newly diagnosed, has ...

DRUG: Decitabine and Cedazuridine

DRUG: Gilteritinib

DRUG: Venetoclax

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin ...
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (H...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

BIOLOGICAL: Filgrastim

DRUG: Ibrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Pegfilgrastim

OTHER: Pharmacological Study

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Re...
This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does not respond to treatmen...

DRUG: Gemtuzumab Ozogamicin

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

OTHER: Quality-of-Life Assessment

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloa...

DRUG: Fludarabine

DRUG: Cytoxan

RADIATION: Total Body Irradiation

PROCEDURE: Allogeneic Blood or Marrow Transplant

PROCEDURE: Peripheral Blood Stem Cell Transplant

DRUG: Mycophenolate Mofetil

DRUG: Sirolimus

DRUG: Tacrolimus

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to C...
This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Pirtobrutinib

DRUG: Venetoclax

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletio...
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft modification technique (selecti...

DEVICE: Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPB...

DRUG: EGFR FPBMC

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants W...
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adve...

DRUG: Obinutuzumab

DRUG: ABBV-453

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

DRUG: HMPL-306

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspet...
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 ...

DRUG: Tuspetinib

DRUG: Venetoclax Oral Tablet

DRUG: Azacitidine for Intravenous Infusion

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL a...
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

DRUG: ATRA

DRUG: Pembrolizumab

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dex...
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating patients with multiple myelo...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Chest Radiography

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

PROCEDURE: Low Dose Computed Tomography of the Whole Body

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

PROCEDURE: X-Ray Imaging

OTHER: Questionnaire Administration

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After ...
This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Some...

DRUG: Cholestyramine

DRUG: Leflunomide

DRUG: Steroid Therapy

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Ma...
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

DRUG: EP31670

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib

DRUG: Ruxolitinib

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK ...
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: Cetuximab

DRUG: TROP2-CAR-NK Cells

DRUG: Rimiducid (AP1903)

PROCEDURE: Lymphodepleting Chemotherapy

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleuce...
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical t...

DRUG: Cyclophosphamide

DRUG: Ciltacabtagene Autoleucel

RADIATION: Total body irradiation

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

DRUG: DR-01

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TAC...
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; ...

DRUG: durvalumab

DRUG: Doxorubicin-Eluting Beads

PROCEDURE: TACE

DRUG: bevacizumab

DRUG: Tremelimumab

A Study of BGB-11417 in Participants With Myeloid Malignancies
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome...

DRUG: BGB-11417

DRUG: Azacitidine

DRUG: Posaconazole

DRUG: BGB-11417

DRUG: BGB-11417

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leu...
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a mo...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

BIOLOGICAL: BAFFR-CAR T cells

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

DRUG: Venetoclax

DRUG: Zanubrutinib

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomali...
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regime...

DRUG: Selinexor

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone Oral

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant uti...

DRUG: Busulfan

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: rabbit ATG

DRUG: G-CSF

BIOLOGICAL: Peripheral blood stem cell

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refracto...
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and...

DRUG: BMS-986458

DRUG: Rituximab

Cevostamab Following CAR T Cell Therapy for RRMM
This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed...

DRUG: Cevostamab

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematolo...
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory A...

DRUG: SLS009

DRUG: venetoclax

DRUG: azacitidine

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (...
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

DRUG: Ruxolitinib Oral Tablet [Jakafi]

DRUG: Lenalidomide

DRUG: Methylprednisolone

Asciminib Roll-over Study
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

DRUG: Asciminib single agent

DRUG: Imatinib

DRUG: Nilotinib

DRUG: Bosutinib

DRUG: Dasatinib

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B...
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard...

DRUG: alpha beta depletion

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/...
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-li...

DRUG: Ibrutinib

DRUG: HD- Methotrexate (MTX)

DRUG: Rituximab + HD- Methotrexate (MTX)

DRUG: procarbazine

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refr...
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

BIOLOGICAL: BMS-986393

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the ...
Background: A new cancer therapy takes white blood cells from a person, grows them in a lab, genetically changes them, then gives them back to the person. Researchers think this may help attack tumors in people with certain cancers. It is called gen...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Aldesleukin

BIOLOGICAL: anti-KRAS G12D mTCR PBL

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Stud...
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collec...

DRUG: decitabine

DRUG: spartalizumab

DRUG: sabatolimab

DRUG: azacitidine

DRUG: venetoclax

DRUG: INQOVI (oral decitabine)

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (...

DRUG: Belantamab mafodotin

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use i...

DRUG: Bomedemstat

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advance...

DRUG: ATG-031

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for childre...

DRUG: Obinutuzumab

DRUG: Liposomal ARA-C

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come...

BIOLOGICAL: CD30.CAR-EBVST cells

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
This phase II trial studies the effect of venetoclax and azacitidine in treating patients with therapy related or secondary myelodysplastic syndrome. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell s...

DRUG: Azacitidine

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Venetoclax

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, ...
This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cell...

BIOLOGICAL: Canakinumab

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangemen...
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and ot...

DRUG: NVL-655

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time th...

BIOLOGICAL: Linvoseltamab

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic ...
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies ...

DRUG: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)

DEVICE: JH-DSA Semi-Quant Screen and Response Score

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Ref...
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory highe...

DRUG: GLB-001

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Ly...
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow ...

DRUG: Ibrutinib

BIOLOGICAL: Obinutuzumab

OTHER: Laboratory Biomarker Analysis

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical a...

BIOLOGICAL: UCART20x22

BIOLOGICAL: CLLS52

A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab...
This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia or ly...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

DRUG: Ruxolitinib

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic...
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

DRUG: Ibrutinib

DRUG: Venetoclax

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back...

DRUG: Polatuzumab vedotin (PV)

DRUG: Rituximab

DRUG: Hyaluronidase

DRUG: Gemcitabine

DRUG: Cisplatin

DRUG: Dexamethasone

DRUG: GCSF

JSP191 (Briquilimab) in Subjects With LR-MDS
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

DRUG: JSP191

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richt...
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names ...

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Polatuzumab Vedotin

DRUG: Atezolizumab

DRUG: Tocilizumab

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple ...
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, s...

DRUG: selinexor

DRUG: carfilzomib

DRUG: dexamethasone

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

DRUG: N-Acetylcysteine

Study of Tazemetostat in Lymphoid Malignancies
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received ...

DRUG: Tazemetostat

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies
This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation stu...

BIOLOGICAL: DSP107

DRUG: Azacitidine

DRUG: Venetoclax

SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

BIOLOGICAL: SynKIR-310

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pne...
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mes...

OTHER: Best Practice

BIOLOGICAL: Mesenchymal Stem Cell

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknow...
This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of eithe...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Canakinumab

PROCEDURE: Chest Radiography

PROCEDURE: Echocardiography

DRUG: Placebo Administration

OTHER: Quality-of-Life Assessment

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory...
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children ...

DRUG: Luveltamab tazevibulin

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and ...
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back...

GENETIC: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells

GENETIC: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Ce...
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maint...

DRUG: Iberdomide

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemi...
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vinc...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Nelarabine

DRUG: Pegaspargase

DRUG: Prednisone

DRUG: Venetoclax

DRUG: Vincristine Sulfate

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive No...
The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.

DRUG: Mosunetuzumab

DRUG: Polatuzumab

BIOLOGICAL: CAR-T Cell Therapy

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relaps...
This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing ...

BIOLOGICAL: Anti-CD19 CAR-T cells

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body fr...

BIOLOGICAL: ATLCAR.CD30.CCR4 cells

BIOLOGICAL: ALTCAR.CD30 cells

DRUG: Bendamustine

DRUG: Fludarabine

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasm...
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part...

DRUG: JNJ-88549968

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination ...

DRUG: FHD-286

DRUG: Low Dose Cytarabine

DRUG: Decitabine

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults ...
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapse...

DRUG: Epcoritamab

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethaso...
BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included...

DRUG: Isavuconazole

DRUG: TEDDI

BIOLOGICAL: Rituximab

DRUG: Cytarabine

DRUG: TEDD

DRUG: Ibrutinib (Arms 2, 3 and 4)

DRUG: Methotrexate

DRUG: Ibrutinib (Arm 1 - Closed with Amendment G)

DRUG: Ibrutinib (Arm 4)

Pembro Plus CAR T-cell Therapy in R/R in PMBCL
This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the ...

DRUG: Pembrolizumab

DRUG: Lymphodepletion Chemotherapy

DRUG: Chimeric Antigen Receptor (CAR) Therapy Infusion

PROCEDURE: Leukapheresis

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission ...
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epc...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Epcoritamab

PROCEDURE: Magnetic Resonance Imaging

OTHER: Patient Observation

PROCEDURE: Positron Emission Tomography

Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressi...
The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone, vincristine sulfate (Oncov...

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Prednisone

DRUG: Loncastuximab Tesirine 0.075 mg/kg by IV

DRUG: Loncastuximab tesirine 0.12 mg/kg by IV

DRUG: Loncastuximab tesirine 0.15 mg/kg by IV

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy ...
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidom...

DRUG: Lenalidomide

DRUG: Daratumumab/rHuPH20

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib

DRUG: Dabrafenib

DRUG: Trametinib

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with ...
Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing sc...

DRUG: CD38-SADA:177Lu-DOTA Complex

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor...

DRUG: SIM1811-03

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relap...
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. Th...

DRUG: KRT-232

DRUG: Best Available Therapy (BAT)

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKAL...
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. There is no standard treatment for the cancer at this time or the currently used treatments do not work completely in all...

BIOLOGICAL: Kappa CD28 T cells

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

DRUG: ONO-4685

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a ye...

DRUG: Azacitidine

DRUG: Decitabine

DRUG: Venetoclax

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patien...
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludar...

BIOLOGICAL: Dilanubicel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Electrocardiography

PROCEDURE: Computed Tomography

Venetoclax and Lintuzumab-Ac225 in AML Patients
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage ...

BIOLOGICAL: Lintuzumab-Ac225

DRUG: Venetoclax

DRUG: Spironolactone

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This...

DRUG: Belinostat Injection

DRUG: Pralatrexate Injection

DRUG: CHOP

DRUG: COP

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

DRUG: APG-2575

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC admin...

DRUG: Blinatumomab

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for th...
This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy reduced-intensity condition...

DRUG: Cladribine

DRUG: Cyclophosphamide

DRUG: Cyclosporine

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mitoxantrone

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Idarubicin

DRUG: Fludarabine

DRUG: Cytarabine

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: X-Ray Imaging

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leuke...
This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refr...

DRUG: Oral Azacitidine

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in ...
This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on patients with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effec...

DRUG: Ravulizumab

DRUG: Pozelimab

DRUG: Cemdisiran

DRUG: Eculizumab

Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
Tranexamic acid (TXA) is a synthetic, competitive lysine receptor inhibitor on plasminogen. It ultimately stabilizes the fibrin matrix, therefore used as a hemostatic agent for various indications. While there has been indications for orthopedic and ...

DRUG: Tranexamic acid

DRUG: Placebo

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feas...

BIOLOGICAL: 8/12-Day Production of Car-T Cells

BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells

BIOLOGICAL: 12-Day Production of Car-T Cells

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer ...

DRUG: Mosunetuzumab

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.

DRUG: Methotrexate

DRUG: Rituximab

DRUG: leucovorin

DRUG: Glucarpidase

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide ...
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib ha...

DRUG: Bortezomib

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called ...

DRUG: Brentuximab vedotin

DRUG: Doxorubicin

DRUG: Vinblastine

DRUG: Dacarbazine

DRUG: Pembrolizumab

DRUG: Gemcitabine

DRUG: Vinorelbine

DIAGNOSTIC_TEST: FDG-PET/CT scan

Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 12...
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/...

DRUG: reparixin

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
This phase II trial tests how well adding lisocabtagene maraleucel (liso-cel) to nivolumab and ibrutinib works in treating patients with Richter's transformation. Liso-cel is in a class of medications called autologous cellular immunotherapy, a type ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Ibrutinib

BIOLOGICAL: Lisocabtagene Maraleucel

BIOLOGICAL: Nivolumab

PROCEDURE: Pheresis

PROCEDURE: Positron Emission Tomography

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed t...

DRUG: MGD024

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressi...
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2 for t...

DRUG: Odronextamab

DRUG: REGN5837

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (AC...
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who...

DRUG: Luspatercept

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. * This research study involves the study drug belantamab mafodotin. * Belantamab ...

DRUG: Belantamab Mafodotin

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Duvelisib

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

PROCEDURE: Punch Biopsy

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Deci...
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML...

DRUG: SNDX-5613

DRUG: Venetoclax

DRUG: ASTX727

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase Ib trial tests the safety, side effects and best dose of ST-067 in combination with teclistamab and how well it works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not re...

BIOLOGICAL: Vevoctadekin

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

OTHER: Medical Chart Review

DRUG: Teclistamab

PROCEDURE: Biospecimen Collection

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs f...
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the k...

DRUG: CAR.k.28

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
The purpose of this study is to test the safety and efficacy (benefits) of an investigational drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been administered to patients with various solid tumors. In this study, LB-10...

DRUG: LB-100

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelody...
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syn...

DRUG: Tamibarotene

DRUG: Placebo

DRUG: Azacitidine

CART-38 in Adult AML and MM Patients
This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patien...

DRUG: 3x10(6) CART-38 cellls

DRUG: 7x10(5) CART-38 cells

DRUG: 7x10(6) CART-38 cells

DRUG: 3x10(7) CART-38 cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

BIOLOGICAL: P-CD19CD20-ALLO1

DRUG: Rimiducid

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose R...
This study is an open-label Phase II trial of non-Hodgkin lymphoma patients receiving initial treatment with the immunomodulatory agent, pembrolizumab, plus low-dose (4 Gy x 5) involved-site radiotherapy. Eligible patients will have r/r disease with ...

DRUG: Pembrolizumab

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Fu...
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants...

DRUG: Belantamab mafodotin

newsletter icon

Get the latest thought leadership on your Diffuse Large B Cell Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Follow Us

facebook instagram youtube